無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

グリメピリドの中国市場

Investigation Report on China's Glimepiride Market, 2018-2022

発行 China Research and Intelligence 商品コード 334099
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.61円で換算しております。
Back to Top
グリメピリドの中国市場 Investigation Report on China's Glimepiride Market, 2018-2022
出版日: 2018年11月29日 ページ情報: 英文 30 Pages
概要

中国におけるグリメピリドの売上額は、2005年から2014年にかけて30.7%のCAGRで拡大し、2014年には2億2400万人民元に達しました。

当レポートでは、中国のグリメピリド市場について調査し、グリメピリドの効能・効果、中国市場における特許および承認の状況、売上・販売量の推移と予測、価格動向、主要メーカーと市場シェア、競合環境とその展望、主要メーカーのプロファイルなどをまとめています。

第1章 グリメピリドの関連概念

  • 適応
  • 世界市場における販売状況

第2章 中国におけるグリメピリドの市場プロファイル

  • 特許状況
  • 主要製薬会社
  • 市場規模

第3章 中国におけるグリメピリドの販売状況調査

  • 販売額
    • 総販売額
    • 地域別の販売額
  • 販売量
    • 総販売量
    • 地域別の販売数

第4章 中国におけるグリメピリドの主要製薬会社の市場シェア調査

  • 販売額ベースの市場シェア
  • 販売量ベースの市場シェア

第5章 中国におけるグリメピリドの剤形に関する調査

  • 剤形別の市場シェア:販売額ベース
  • 剤形別の市場シェア:販売量ベース

第6章 中国の病院におけるグリメピリドの基準価格

  • Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd (商品名:Amaryl)
  • Aventis(Italy)
  • Wanbang Biopharmaceuticals
  • Zhongnuo Pharma
  • Tianan Pharmaceutical
  • Guangzhou Hairui Pharmaceutical Co., Ltd
  • Sichuan Pudu Pharmaceutical Plant

第7章 中国市場におけるグリメピリドの主要製薬会社

  • Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd
  • Aventis(Italy)
  • Wanbang Biopharmaceuticals
  • Zhongnuo Pharma
  • Tianan Pharmaceutical
  • Guangzhou Hairui Pharmaceutical Co., Ltd

第8章 中国におけるグリメピリドの市場見通し

  • 市場規模の予測
  • 競合情勢の予測
目次
Product Code: 1811352

Description

Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi's brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995. Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin. For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.

According to CRI, with the development of China's economy, the rise of urbanization level, and the aging of population, the life style of Chinese people is changing, which increases the obese population and the incidence of diabetes in China. It is estimated that the number of type 2 diabetic patients in China had surpassed 1 million by the end of 2017, and is growing by 1.5 million to 2 million every year. The growing number of diabetics in China promotes the growth of the antidiabetic drug market.

According to CRI, generic products have sprung up one after another since 2004 when Sanofi (Beijing) Pharmaceutical Co., Ltd. launched Amaryl in China. In 2017, the market size of Glimepiride in China was about CNY 302 million. There are over 10 Glimepiride manufacturers in China. The major market players include Sanofi (Beijing) Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. By sales value, in 2017, Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Amaryl captured more than 80% share of China's Glimepiride market.

It is expected that as the number of diabetics continues to grow, China's Glimepiride market will have huge growth potential in the next few years.

Topics Covered:

  • Situation of diabetes in China
  • Sales of Glimepiride in China
  • Competition on China's Glimepiride market
  • Prices of Glimepiride in China
  • Forecasts on China's Glimepiride market from 2018 to 2022

Table of Contents

Table of Contents

1 Relevant Concepts of Glimepiride

  • 1.1 Indications for Glimepiride
  • 1.2 Development of Glimepiride in China
  • 1.3 Governmental Approval of Glimepiride in China

2 Sales of Glimepiride in China, 2013-2017

  • 2.1 Sales Value of Glimepiride
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Glimepiride
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Glimepiride by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Capsules
    • 2.3.3 Pills

3 Analysis on Major Glimepiride Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Glimepiride Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Sanofi (Beijing) Pharmaceutical Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in China
  • 3.3 Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in China
  • 3.4 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
  • 3.5 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.
  • 3.6 Sanofi

4 Prices of Glimepiride in China, 2017-2018

  • 4.1 Sanofi (Beijing) Pharmaceutical Co., Ltd. (Amaryl)
  • 4.2 Jiangsu Wanbang Biopharmaceuticals Co., Ltd. (Wansuping)
  • 4.3 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Linmeixin)
  • 4.4 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. (Yousu)
  • 4.5 Sanofi (Amaryl)

5 Prospect of China's Glimepiride Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Sales of Glimepiride in China, 2013-2017
  • Chart Sales Value of Glimepiride in Parts of China, 2013-2017
  • Chart Sales Volume of Glimepiride in China, 2013-2017
  • Chart Sales Volume of Glimepiride in Parts of China, 2013-2017
  • Chart Sales Value of Glimepiride Tablets in China, 2013-2017
  • Chart Sales Volume of Glimepiride Tablets in China, 2013-2017
  • Chart Sales Value of Glimepiride Capsules in China, 2013-2017
  • Chart Sales Value of Glimepiride Pills in China, 2013-2017
  • Chart Sales Volume of Glimepiride Pills in China, 2013-2017
  • Chart Market Share of Top 5 Glimepiride Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Glimepiride Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Volume of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of Sanofi's Glimepiride, 2013-2017
  • Chart Prices of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Sanofi's Glimepiride in Parts of China, 2017-2018
Back to Top